Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements

Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial

(2019) Kathleen E. Corey et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease

(2019) Ankur Srivastava et al.   BMC GASTROENTEROLOGY

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

(2019) Mary E. Rinella et al.   JOURNAL OF HEPATOLOGY

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood

(2019) Seamus Kent et al.   PHARMACOECONOMICS

Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis

(2019) Catriona Crossan et al.   LIVER INTERNATIONAL

Nonalcoholic Fatty Liver Disease and Metabolic Syndrome

(2018) Donghee Kim et al.   Clinics in Liver Disease

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Determinants of fibrosis progression and regression in NASH

(2018) Detlef Schuppan et al.   JOURNAL OF HEPATOLOGY

Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge

(2018) Andrew J. Palmer et al.   VALUE IN HEALTH

Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand

(2018) Bunchai Chongmelaxme et al.   PHARMACOECONOMICS

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases

(2017) Leon A Adams et al.   GUT

Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis

(2017) Matthew J. Klebanoff et al.   HEPATOLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients

(2017) Pochamana Phisalprapa et al.   MEDICINE

Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study

(2017) Lukasz Tanajewski et al.   BMJ Open

Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis

(2016) Kathleen E. Corey et al.   DIGESTIVE DISEASES AND SCIENCES

Pathogenesis of Nonalcoholic Steatohepatitis

(2016) Mariana Verdelho Machado et al.   GASTROENTEROLOGY

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

(2016) Zobair M. Younossi et al.   HEPATOLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging

(2016) Laurence Blake et al.   BMJ Open

A Health Technology Assessment of Transient Elastography in Adult Liver Disease

(2016) Rodney Steadman et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score

(2016) Elliot B. Tapper et al.   PLoS One

Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography

(2015) Elliot B Tapper et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Cost-utility analysis of nonalcoholic steatohepatitis screening

(2015) Eric Zhang et al.   EUROPEAN RADIOLOGY

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation

(2015) Catriona Crossan et al.   HEALTH TECHNOLOGY ASSESSMENT

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

(2015) Erin K. Spengler et al.   MAYO CLINIC PROCEEDINGS

AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users

(2015) P. Vemer et al.   PHARMACOECONOMICS

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels

(2014) K. E. Corey et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis

(2012) Suzanne E. Mahady et al.   HEPATOLOGY

Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1

(2012) J. Jaime Caro et al.   VALUE IN HEALTH

Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2

(2012) Mark Roberts et al.   VALUE IN HEALTH

Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7

(2012) David M. Eddy et al.   VALUE IN HEALTH

Endpoints and clinical trial design for nonalcoholic steatohepatitis

(2011) Arun J. Sanyal et al.   HEPATOLOGY

Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Noreen Hossain et al.   Clinical Gastroenterology and Hepatology

Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network

(2009) Kristin David et al.   HEPATOLOGY

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression

(2008) Hla-Hla Thein et al.   HEPATOLOGY